The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page guideline outlining optimal guidance for use of laboratory analysis in the diagnosis and management of diabetes.
At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.